Health Products Regulatory Authority

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Lercaril 10 mg/10 mg film-coated tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 10 mg enalapril maleate (equivalent to 7.64 mg enalapril) and 10 mg lercanidipine hydrochloride (equivalent to 9.44 mg lercanidipine).

Excipient with known effect: lactose monohydrate.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Film-coated tablet.

Product imported from Spain: White, circular, biconvex tablets of 8.5 mm

4 CLINICAL PARTICULARS

As per PA1404/002/001

5 PHARMACOLOGICAL PROPERTIES

As per PA1404/002/001

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Core:

Lactose monohydrate Cellulose microcrystalline Sodium starch glycolate Type A Povidone K30 Sodium hydrogen carbonate Magnesium stearate

Film-Coating:

Hypromellose 5 cP Titanium dioxide (E171) Talc Macrogol 6000

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

The shelf life expiry date of this product shall be the date shown on the blister and outer package of the product on the market in the country of origin.

07 May 2021 CRN00C8P6 Page 1 of 2

Health Products Regulatory Authority

6.4 Special precautions for storage

Store in the original package in order to protect from light and moisture. Do not store above 25°C.

6.5 Nature and contents of container

Blisters containing 28 tablets.

6.6 Special precautions for disposal

Any unused product or waste material should be disposed of in accordance with local requirements.

7 PARALLEL PRODUCT AUTHORISATION HOLDER

PCO Manufacturing Ltd.
Unit 10, Ashbourne Business Park
Rath
Ashbourne
Co. Meath
Ireland

8 PARALLEL PRODUCT AUTHORISATION NUMBER

PPA0465/472/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 7th May 2021

10 DATE OF REVISION OF THE TEXT

07 May 2021 CRN00C8P6 Page 2 of 2